Last reviewed · How we verify
Flucelvax Quadrivalent vaccine
Flucelvax Quadrivalent is an inactivated influenza vaccine produced using cell culture technology that stimulates immune response against four strains of influenza virus.
Flucelvax Quadrivalent is an inactivated influenza vaccine produced using cell culture technology that stimulates immune response against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Flucelvax Quadrivalent vaccine |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza virus antigens from four seasonal flu strains (two A subtypes and two B lineages) grown in mammalian cell culture rather than eggs. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cellular immune responses that provide protection against infection with matching influenza strains.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flucelvax Quadrivalent vaccine CI brief — competitive landscape report
- Flucelvax Quadrivalent vaccine updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI